AbbVie Dividends and Buybacks
Dividend criteria checks 4/6
AbbVie is a dividend paying company with a current yield of 3.53%.
Key information
3.5%
Dividend yield
0.4%
Buyback Yield
| Total Shareholder Yield | 3.9% |
| Future Dividend Yield | 3.9% |
| Dividend Growth | 12.2% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | 272% |
Recent dividend and buyback updates
AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year
Jan 03
AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.64
Dec 09Recent updates
AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear
May 16AbbVie Q1 Earnings Review: Typically Strong Performance, Aesthetics Aside
Apr 25AbbVie: Thriving Beyond Humira's Patent Cliff (Upgrade)
Apr 09AbbVie Vs. Sanofi: Which Is The Better Investment Right Now
Mar 28AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
Mar 13Investors Don't See Light At End Of AbbVie Inc.'s (NYSE:ABBV) Tunnel
Feb 25Why AbbVie Remains A Strong Buy For Long-Term Investors
Feb 23AbbVie: An Undervalued Dividend Aristocrat
Feb 14AbbVie: Q4 2024 Earnings Preview And Update On Emraclidine
Jan 26AbbVie's Stock Is Unfairly Cheap
Jan 09AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year
Jan 03Betting Big On AbbVie: A Prescription For Growth And Dividends
Dec 11AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.64
Dec 09AbbVie: Upgrading To 'Strong Buy' After Pullback
Nov 22AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.64
Nov 19AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear
Nov 12AbbVie Stock: Keep Calm And Buy The Dip
Nov 11AbbVie: 3 Positives From The Earnings Report
Oct 30AbbVie: Strong Dividends But Humira Disappoints
Oct 22AbbVie: Dividend Discount Model Suggests Large Valuation Risks
Sep 29We Think AbbVie (NYSE:ABBV) Can Stay On Top Of Its Debt
Sep 06Why AbbVie Remains One Of My Favorite Dividend Growers
Aug 27AbbVie: Growth Is Still A Better Choice
Jul 29Stability and Growth of Payments
Fetching dividends data
Stable Dividend: ABBV's dividends per share have been stable in the past 10 years.
Growing Dividend: ABBV's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
| AbbVie Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (ABBV) | 3.5% |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.7% |
| Industry Average (Biotechs) | 2.2% |
| Analyst forecast (ABBV) (up to 3 years) | 3.9% |
Notable Dividend: ABBV's dividend (3.53%) is higher than the bottom 25% of dividend payers in the US market (1.54%).
High Dividend: ABBV's dividend (3.53%) is low compared to the top 25% of dividend payers in the US market (4.67%).
Earnings Payout to Shareholders
Earnings Coverage: With its high payout ratio (271.6%), ABBV's dividend payments are not well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: At its current cash payout ratio (75.3%), ABBV's dividend payments are covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 11:57 |
| End of Day Share Price | 2025/05/19 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AbbVie Inc. is covered by 51 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Luisa Hector | Berenberg |
| Evan Seigerman | BMO Capital Markets Equity Research |